Teladoc (TDOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
I've upgraded Teladoc to a tepid buy—not a full conviction call, but the numbers finally tilt in its favor. I believe the company's innovative platform positions it as a leader in digital healthcare, driving long-term value. 7x forward free cash flow is just too low to ignore, even with weak top-line growth.
Teladoc (TDOC) concluded the recent trading session at $8.58, signifying a -1.49% move from its prior day's close.
Teladoc (TDOC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
In the most recent trading session, Teladoc (TDOC) closed at $7.02, indicating a +2.33% shift from the previous trading day.
Teladoc Health, Inc. (NYSE:TDOC ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 11:30 AM ET Company Participants Charles Divita - CEO & Director Mala Murthy - Chief Financial Officer Conference Call Participants David Harrison Roman - Goldman Sachs Group, Inc., Research Division David Harrison Roman Very pleased to welcome the management team from Teladoc, Chuck Divita, Chief Executive Officer; and Mala Murthy, Chief Financial Officer. Very much appreciate you taking the time to participate in the conference and look forward to getting an update on Teladoc here.
In the closing of the recent trading day, Teladoc (TDOC) stood at $7.40, denoting a +1.79% change from the preceding trading day.
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock?
Teladoc Health expects Integrated Care members to be between 101 million and 103 million in 2025.
Teladoc Health, Inc. (NYSE:TDOC ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Corporate Participants Mike Minchak - Head of Investor Relations Chuck Divita - Chief Executive Officer Mala Murthy - Chief Financial Officer Conference Call Participants Jessica Tassan - Piper Sandler David Roman - Goldman Sachs Daniel Grosslight - Citi Eduardo Ron - Truist Elizabeth Anderson - Evercore Charles Rhyee - Cowen Operator Good afternoon, thank you for attending today's Teladoc Health First Quarter 2025 Earnings Call. My name is Cole and I'll be the moderator for today's call.
The headline numbers for Teladoc (TDOC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Teladoc (TDOC) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.49 per share a year ago.